Intech Biopharm Ltd (6461) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.085x

Based on the latest financial reports, Intech Biopharm Ltd (6461) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-84.50 Million ≈ $-2.66 Million USD) by net assets (NT$991.64 Million ≈ $31.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Intech Biopharm Ltd worth for the company's overall valuation and market capitalisation.

Intech Biopharm Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Intech Biopharm Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Intech Biopharm Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Intech Biopharm Ltd ranked by their cash flow conversion efficiency. See how well can Intech Biopharm Ltd service its debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.) NASDAQ:LION	0.172x
Koryo Credit Information Co. Ltd KQ:049720	0.133x
Téléverbier SA PA:TVRB	0.232x
KCC Engineering & Construction Co. Ltd KQ:021320	0.117x
Biotalys NV BR:BTLS	-0.154x
Enterprise Group Inc TO:E	0.006x
ASolid Technology Co Ltd TWO:6485	0.027x
Kumkang Kind KO:014280	-0.020x

Annual Cash Flow Conversion Efficiency for Intech Biopharm Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Intech Biopharm Ltd from 2017 to 2025. View latest Intech Biopharm Ltd stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$1.10 Billion ≈ $34.69 Million	NT$-361.13 Million ≈ $-11.38 Million	-0.328x	+0.79%
2024-12-31	NT$814.28 Million ≈ $25.65 Million	NT$-269.22 Million ≈ $-8.48 Million	-0.331x	-89.15%
2023-12-31	NT$1.17 Billion ≈ $36.79 Million	NT$-204.13 Million ≈ $-6.43 Million	-0.175x	+5.28%
2022-12-31	NT$1.03 Billion ≈ $32.50 Million	NT$-190.39 Million ≈ $-6.00 Million	-0.185x	-23.05%
2021-12-31	NT$1.34 Billion ≈ $42.14 Million	NT$-200.61 Million ≈ $-6.32 Million	-0.150x	-19.06%
2020-12-31	NT$1.33 Billion ≈ $41.86 Million	NT$-167.38 Million ≈ $-5.27 Million	-0.126x	-4.52%
2019-12-31	NT$1.57 Billion ≈ $49.43 Million	NT$-189.09 Million ≈ $-5.96 Million	-0.121x	+22.84%
2018-12-31	NT$1.49 Billion ≈ $46.88 Million	NT$-232.43 Million ≈ $-7.32 Million	-0.156x	-45.69%
2017-12-31	NT$1.36 Billion ≈ $42.70 Million	NT$-145.29 Million ≈ $-4.58 Million	-0.107x	--

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$85.33 Million

NT$2.71 Billion TWD

Market Cap Rank

#19864 Global

#1141 in Taiwan

Share Price

NT$24.55

Change (1 day)

-0.20%

52-Week Range

NT$14.40 - NT$26.92

All Time High

NT$57.64